229 related articles for article (PubMed ID: 29504582)
1. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
Trejo P; Rauch F; Ward L
J Musculoskelet Neuronal Interact; 2018 Mar; 18(1):76-80. PubMed ID: 29504582
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
5. Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
Seale E; Molina MO; Carsen S; Sheffield H; Koujok K; Robinson ME; Feber J; Smit K; Page M; Walker S; Khan N; Konji VN; Rauch F; Ward LM
Calcif Tissue Int; 2023 May; 112(5):613-620. PubMed ID: 36867194
[TBL] [Abstract][Full Text] [Related]
6. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
Ward L; Bardai G; Moffatt P; Al-Jallad H; Trejo P; Glorieux FH; Rauch F
Calcif Tissue Int; 2016 Jun; 98(6):566-72. PubMed ID: 26815784
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
[TBL] [Abstract][Full Text] [Related]
8. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
10. Two years' experience with denosumab for children with osteogenesis imperfecta type VI.
Hoyer-Kuhn H; Netzer C; Koerber F; Schoenau E; Semler O
Orphanet J Rare Dis; 2014 Sep; 9():145. PubMed ID: 25257953
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
Hoyer-Kuhn H; Franklin J; Allo G; Kron M; Netzer C; Eysel P; Hero B; Schoenau E; Semler O
J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):24-32. PubMed ID: 26944820
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
[TBL] [Abstract][Full Text] [Related]
13. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
Tan JY; Seow CJ
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings.
Li G; Jin Y; Levine MAH; Hoyer-Kuhn H; Ward L; Adachi JD
Acta Paediatr; 2018 Mar; 107(3):534-537. PubMed ID: 29154388
[No Abstract] [Full Text] [Related]
15. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
16. TBS as a Tool to Differentiate the Impact of Antiresorptives onCortical and Trabecular Bone in Children With OsteogenesisImperfecta.
Rehberg M; Winzenrieth R; Hoyer-Kuhn H; Duran I; Schoenau E; Semler O
J Clin Densitom; 2019; 22(2):229-235. PubMed ID: 30309730
[TBL] [Abstract][Full Text] [Related]
17. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
18. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab.
Hoyer-Kuhn H; Stark C; Franklin J; Schoenau E; Semler O
Pediatr Endocrinol Rev; 2017 Nov; 15(Suppl 1):123-129. PubMed ID: 29292876
[TBL] [Abstract][Full Text] [Related]
20. Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?
Celik NB; Gonc N; Ozon A; Alikasifoglu A; Rauch F; Kandemir N
J Pediatr Endocrinol Metab; 2020 Dec; 33(12):1617-1624. PubMed ID: 33031053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
